N/A
N=21
Evaluation of Daytime Corneal Swelling During Wear of Galyfilcon A Lenses
Myopia
Bottom Line
View on ClinicalTrials.gov: NCT01482819 ↗Enrolled (actual)
21
Serious AEs
0.0%
Results posted
Apr 2015
Primary outcome: Primary: Corneal Swelling — 569.42; 574.64; 575.57; 578.99 microns
Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- galyfilcon A (Device); galyfilcon A plus (Device); lotrafilcon A (Device); polymacon (Device); spectacles (Other)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- Johnson & Johnson Vision Care, Inc.
- Primary completion
- Dec 2011
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Corneal Swelling |
569.42; 574.64; 575.57; 578.99; 573.79 | — |
| PRIMARY Limbal Redness |
0.66; 0.83; 0.77; 0.91; 1.14 | — |
| PRIMARY Endothelia Blebs |
4.97; 8.86; 10.93; 10.31; 8.50 | — |
Summary
The purpose of this study is to evaluate corneal swelling, limbal redness, and endothelial bleb response to wearing galyfilcon A lenses in asian eyes.
Eligibility Criteria
Inclusion Criteria
- Be of legal age (i.e. 18 years)
- Be of Asian descent and have -Asian eye‖ identifying features (see Appendix A)
- Be mentally competent, willing and able to sign a written informed consent form.
- Have contact lens distance sphere requirement in the range 1.00D to 6.00D.
- Have spectacle astigmatism <1.25D in each eye
- Currently wear soft contact lenses (for at least 3 months prior to the trial ) without experiencing difficulties or contact lens related complications
- Have had an oculo-visual examination within the previous 12 months.
- Have normal eyes with no evidence of abnormality or disease. For the purposes of this study a normal eye is defined as one having:
- No evidence of lid abnormality or infection
- No conjunctival abnormality or infection
- No clinically significant slit lamp findings (i.e. edema, staining, scarring, vascularization, infiltrates or abnormal opacities)
- No other active ocular disease
Exclusion Criteria
- Requires concurrent ocular medication.
- Clinically significant (Grade 3 or 4) corneal staining (FDA scale), corneal stromal haze, corneal vascularization, tarsal abnormalities, bulbar hyperemia, limbal hyperemia, or any other abnormality of the cornea that would contraindicate contact lens wear.
- Has had refractive surgery.
- Has had any anterior ocular surgery. Has had any other ocular surgery or injury within 8 weeks immediately prior to enrolment for this study.
- History of abnormal lachrymal secretions.
- Pre-existing ocular irritation that would preclude contact lens fitting.
- Keratoconus or other corneal irregularity.
- Extended lens wear in last 3 months.
- PMMA, hybrid or RGP lens wear in the previous 8 weeks
- Any systemic illness which would contraindicate lens wear or the medical treatment of which would affect vision or successful lens wear.
- Has diabetes
- Known/reported infectious disease (e.g., hepatitis, tuberculosis) or an immunosuppressive disease (e.g., HIV).
- History of chronic eye disease (e.g. glaucoma or ARMD).
- Pregnancy, lactating, or planning a pregnancy at the time of enrolment.
- Participation in any concurrent clinical trial or in last 30 days.
- Family member or employee of the clinical site, investigator or other study staff.
- Currently wears habitual contact lenses on an EW basis.
Data sourced from ClinicalTrials.gov (NCT01482819). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.